Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058925 | 1.00 | MTNR1A (0.55) | MTNR1AMTNR1BHDAC1HDAC2HDAC6 | |
| SCHEMBL3048611 | 1.00 | MTNR1A (0.55) | MTNR1AMTNR1BHDAC1HDAC2HDAC6 | |
| SCHEMBL3067588 | 0.99 | MTNR1A (0.56) | MTNR1AMTNR1BHDAC1HDAC2HDAC6 | |
| SCHEMBL3054181 | 0.90 | MTNR1A (0.53) | MTNR1AMTNR1BHDAC1HDAC2HDAC6 | |
| SCHEMBL3056854 | 0.90 | MTNR1A (0.53) | MTNR1AMTNR1BHDAC1HDAC2HDAC6 | |
| SCHEMBL3048558 | 0.90 | MTNR1A (0.54) | MTNR1AMTNR1BHDAC1HDAC2 | |
| SCHEMBL3058490 | 0.90 | MTNR1A (0.54) | MTNR1AMTNR1BHDAC1HDAC2 | |
| SCHEMBL8080132 | 0.89 | MTNR1A (0.54) | MTNR1AMTNR1BHDAC1HDAC2HDAC6 | |
| SCHEMBL3057617 | 0.89 | MTNR1A (0.59) | MTNR1AMTNR1BHDAC1HDAC2 | |
| SCHEMBL3058846 | 0.87 | MTNR1A (0.54) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | claimed |
| CN-101835778-A | Hdac inhibitor | ARQULE INC | 2010-09-15 | — | — | CN | claimed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| CN-101835778-A | Hdac inhibitor | ARQULE INC | 2010-09-15 | — | — | CN | disclosed |
| WO-2009026446-A9 | HDAC INHIBITORS | ARQULE, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009026446-A2 | HDAC INHIBITORS | ARQULE, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | HDAC5, HDAC1, HDAC4 | MTNR1A 2791/4885MTNR1B 3211/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.